Evaluation of palatability of newly developed fast disintegrating tablet of Kremezin in patient.

Evaluation of palatability of newly developed fast disintegrating tablet of Kremezin in patient. - Evaluation of palatability of Kremezin tablet.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000031986

Enrollment

Registered

2018-03-30

Start date

2018-04-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic renal failure

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 20-80 year-old patients(male and female) Patients who have taken kremezin fine grain at the time of the first questionnaire and have taken medication of it for more than 1 month Patients who give the singed informed consent.

Exclusion criteria

Exclusion criteria: Patients who apply to administration contraindications in the package insert of kremezin Patients who will not see the outpatients clinic within 2 weeks to 2 months Patients who can not communicate due to cognitive deterioration Patients who do not manage medication by themselves and their families Patients who it is hard to swallow Patients who have extraordinary state in oral cavity. Patients who is considered as imappropriate by doctor.

Design outcomes

Primary

Measure	Time frame
Palatability of fast disintegrating tablet of kremezin	—

Secondary

Measure	Time frame
Overall adherence for all medicine prescrived. Adherence for Kremezin formulations. Changes of body weight, BUN, s-Cre and eGFR	—

Countries

Japan

Contacts

Public ContactUchida Shinya

School of Pharmaceutical Sciences University of Shizuoka Department of Pharmaceutical Science

uchidas@u-shizuoka-ken.ac.jp054-264-5234

Outcome results